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Objectives: The aim of the research is to explore the main determinants driving 
the diffusion of new medical technologies. MethOds: We investigated the diffu-
sion two medical technologies: cardiac ablation for atrial fibrillation (CA-AF) and 
left atriage appendage closure (LAAC). Our sample consists of all Italian hospitals 
that adopted the two focal technologies in the period 2009-2012. We classified 
the hospitals according to ownership, type, teaching status and urban location. 
In the first regression we investigate the diffusion, i.e. yearly number of proce-
dures performed by each hospital, in the second one the average frequency of use, 
measured as the average number of days between two subsequent procedures 
in each hospital. Results: Different types of hospitals show different baseline 
trends of diffusion. Public hospitals, both teaching and non-teaching, use less 
CA-AF compared to private non-teaching ones. Among hospital-level variables, 
the use of DRG-based reimbursement has a positive effect on CA-AT diffusion, 
not significant for LAAC. The rank in adoption is an important factor only for 
CA-AF. The impact of the number of other hospitals contemporaneously adopting 
the technology is negative for both technologies, but significant only for CA-AF. 
The average time between two subsequent uses is negatively correlated with the 
diffusion for both technologies. Regional contextual variables, including type of 
funding and socio-economic variables do not show significant impacts, with the 
exception of per capita public health expenditure, that enhances the diffusion 
of both technologies, and the ratio between public health expenditure and GDP 
in the case of CA-AF. The average frequency of use decreases over time for both 
technologies. Neither hospital-level variables nor regional-level ones do not show 
significant effects. The only variable with a significant and negative impact on the 
frequency of use of CA-AF is the number of competitors. cOnclusiOns: These 
results are consistent with previous literature.
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Objectives: There is evidence that in Greece, economic crisis has substantially 
affected chronic patients’ access to health care services. The aim of the study was 
to depict the current situation and identify the challenges and opportunities regard-
ing the management of chronic diseases, in times of economic crisis and auster-
ity from the aspect of both providers and patients. MethOds: Representatives of 
chronic patients and medical associations were invited to participate in a focus 
group session. Four diseases (Type 2 Diabetes, Hypertension, COPD, and Alzheimer) 
were selected based on their epidemiology and socioeconomic impact on the Greek 
health care system. Fifteen representatives participated and their statements were 
recorded, analyzed and categorized into 4 categories. Results: Common issues in 
the management of chronic diseases under study appear to be the low quality of 
health services, fragmented primary care system and absence of specialized cent-
ers for the management of chronic diseases. These problems of the Greek health 
system were found to be magnified because of the recession. Furthermore, the 
increased numbers of unemployed, uninsured and patients at risk of poverty, puts 
additional pressure to the health system and futher undermines the quality of 
the health services. Economic and geographic barriers in access were reported, 
strengthening of the primary health system, development of patient registries, 
patient education regarding self-management and involvement of their associations 
in decision making was considered critical to the improvement of disease manage-
ment. cOnclusiOns: The management of chronic diseases was challenging even 
before the economic crisis in Greece, but the current economic framework poses 
additional threats for the health care system jeopardizing patients’ health and its 
sustainability due to an increased risk for future costs. Investment in patients and 
physicians education regarding chronic diseases management was thought to be 
the key for improving this situation.
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Objectives: Aim of the study was to investigate chronic patients’ out-of-pocket 
expenditures and the percent of the households subjected to catastrophic health 
expenditures (CHE) during the economic crisis. MethOds: A cross-sectional study 
was conducted among 1600 chronic patients suffering from diabetes, hyperten-
sion, COPD and Alzheimer. Patients were asked to indicate the amount they spent 
for primary and secondary health care services and for pharmaceuticals. Current 
household income and income decrease since 2010 were also measured. CHE was 
defined as any amount spent for health which accounts for more than 20% of the 
total household income. Results: 1594 patients responded to the survey (99.6%). 
In 2013, 7.8% of all households with at least one chronic condition patient were sub-
jected to CHE, compared to 3.6% in 2010. The analysis by disease showed that 11.4% 
in 2013 vs 6.2% in 2010 of the Alzheimer patients faced CHE, while the respective 
figures was 8.7% vs 2.9% for the COPD patients, 7.1% vs 3.4% for diabetic patients, 
and 4.2 vs 1.7% for the hypertensive patients. Pharmaceutical expenditures alone 
were deemed catastrophic for 4.6% of all the above patients in 2013 vs 1.6% before 
the introduction of the austerity measures and the health care reforms. Of the 
Alzheimer patients, 6.2% in 2013 vs 2.8% in 2010 faced CHE due to out-of-pocket 
payments for drugs, while the respective figures were found to be 3.4% vs 1.8% 
for the diabetic patients, 2.9% vs 0.9% for COPD patients and 1.7% vs 0.9% for the 
hypertensive patients. cOnclusiOns: After the introduction of austerity measures 
Apixaban (74.82±11.39 years) patients were older versus those who switched to dabi-
gatran (72.46±10.89 years, p< 0.0001) or rivaroxaban (73.50±11.27 years, p= 0.0193). 
Apixaban users (45.4%) were more female compared to dabigatran (38.4%, p= 0.0037) 
and rivaroxaban (40.4%, p= 0.0499). The mean CHADS2 score was higher for apixaban 
users (mean±SD 2.28±1.25) as compared to dabigatran (1.94±1.20, p< 0.0001) and 
rivaroxaban (2.18±1.25, p= NS) users. Apixaban patients had significantly higher 
baseline rates for congestive heart failure (p= 0.0111), hypertension (p= 0.0002), renal 
disease (p= 0.0017) and ischemic stroke/ transient ischemic attack (p= 0.0004) as 
compared to dabigatran users. Apixaban users (2.34±2.12) also had higher mean 
charlson comorbidity index scores as compared to dabigatran users (1.98±1.96, 
p= 0.0002). cOnclusiOns: Patients who switch to apixaban are older and sicker 
as compared to those switching to dabigatran or rivaroxaban. A detailed evaluation 
of patient characteristics on the treatment outcomes in NVAF patients switching 
from warfarin to NOAC is warranted in future.
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Objectives: To assess treatment patterns of lipid-lowering drugs in patients with 
hyperlipidemia or prior cardiovascular (CV) events (myocardial infarction, unsta-
ble angina, revascularization, ischemic stroke, transient ischemic attack or heart 
failure) who experience new CV events. MethOds: A retrospective population-
based cohort study was conducted using Swedish electronic medical records and 
national registers. Patients were included in the study based on a prescription of 
lipid-lowering treatment between January 1, 2006 and December 31, 2006 or history 
of CV events (prior to 2006) and followed until December 31,2012 for identification 
of new CV events and assessment of treatment patterns. Patients were stratified 
into three cohorts based on CV risk level. The index was the date of first new CV 
event during follow-up. All outcomes were assessed during the year following index 
date. Adherence was defined as medical possession ratio (MPR) > 0.80. Persistence 
was defined as no gaps > 60 days in supply of drug used at index date. Results: 
Of patients with CV event history (n= 6881), 49% were not on treatment at index. 
Corresponding data for CV risk equivalent and low/unknown CV risk patients were 
37% (n= 3226) and 38% (n= 2497), respectively. Mean MPR for patients on treatment at 
index was similar across cohorts (0.74–0.75). The proportions of adherent patients 
(60–63%) and persistent patients (56–57%) were also similar across cohorts. Dose 
escalation from the dose at index was seen within all cohorts, most notably for 
patients with low/unknown CV risk as 25% increased the dose after index. 2–3% of 
patients switched to a different drug after index while 5–6% of patients augmented 
treatment by adding another lipid-lowering drug. cOnclusiOns: Almost 50% of 
secondary prevention patients were not on any hyperlipidemia treatment, indi-
cating a potential therapeutic gap. Medication adherence and persistence among 
patients on hyperlipidemia treatment were suboptimal.
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Objectives: DIMATCH-HTA is a cohort study conducted to identify determi-
nants of blood pressure control among Portuguese-speaking African immigrants 
and Portuguese natives. The aim of this analysis is to study the determinants of 
health care utilization among hypertensive patients followed in Primary Health 
Care. MethOds: The sample comprises 1243 unbalanced observations from 513 
patients. Data were collected through questionnaires administered face-to-face 
at baseline, 6 and 12 months, and by telephone at 3 and 9 months after enrol-
ment. The variable used to capture health care utilization was the number of visits 
to the general practitioner related to hypertension, in the three months prior to 
each interview. The covariates were chosen based on Grossman’s health capital 
model of demand for health (1972) and Andersen conceptual model (1968). Amongst 
socioeconomic covariates, gender, age, ethnicity, education, monthly equivalent 
income, living alone and domestic work were considered. Health status was cap-
tured by the presence of diabetes, time since hypertension diagnosis and number 
of medicines. Self-perception of hypertension and private health insurance were 
also included. A GLMM model for count data, with a random effect on intercept 
was estimated. Model adequacy was checked via residual analysis and compari-
son of observed and predicted values. The analysis was performed in R (version 
3.0. 2) using lme4 package. Results: Results of estimated model indicated that 
total number of medicines (beta= 0.05, p-value= 0.03) and diabetes (beta= 0.40, 
p-value= 0.01) have significant positive impact on health care consumption. Patients 
whose occupation is domestic work have higher health care utilization (beta= 0.73, 
p-value= 0.02). On the other hand, those who self-assess their hypertension as con-
trolled (beta= -0.37, p-value= 0.02) and patients with higher income (in log scale, 
beta= -0.26, p-value= 0.01) have less visits to general practitioner related to hyper-
tension. cOnclusiOns: Based on the analysis it seems that not only variables 
related to health status, but also socioeconomic determinants impact health care 
utilization in hypertension.
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